Integrated Molecular Tumor Board (iMTB) for reporting molecular data in precision cancer medicine

Akronym

iMTB-PCMed

Bidragets beskrivning

This proposal aims to develop a system for the prospective real-time reporting of clinically meaningful molecular findings, extracted from cancer patients' research profiling data using the integrative molecular tumor board (iMTB) tool and returned to the clinics via biobank. The iMTB tool and process development takes advantage of the data in iCAN Digital Precision Cancer Medicine Flagship project (www.ican.fi), where each patient's longitudinal health information is combined with molecular profiling data in a secure analysis platform. This project develops iMTB modules for omics and cohort analysis as well as focuses on automation and secure data return of the reports. In addition, we aim to integrate iMTB into hospital electronic health record system to systematically discover and utilize biomarkers of diagnostic, prognostic and therapeutic significance for the benefit of cancer patients.
Visa mer

Startår

2026

Slutår

2028

Beviljade finansiering

Outi Monni
339 794 €



Kontaktperson

Outi Monni

Rollen i Finlands Akademis konsortium

Ledare

Övriga parter i konsortiet

Partner
Helsingfors universitet (373151)
340 026 €
Partner
120 180 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt med särskild inriktning

Beslutfattare

Suomen akatemian muu päättäjä
05.12.2025

Övriga uppgifter

Finansieringsbeslutets nummer

373150

Vetenskapsområden

Genetik, utvecklingsbiologi, fysiologi

Forskningsområden

Perinnöllisyystiede

Identifierade teman

cancer